The University of Arizona has opened a clinical trial testing whether GLP-1 receptor agonist drugs — the class that includes semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) — can be safely used alongside standard chemotherapy in patients with metastatic pancreatic, colorectal, or hepatocellular (liver) cancer.
The trial is registered with ClinicalTrials.gov under identifier NCT07627191, with an estimated start date of June 30, 2026, and an estimated completion date of June 30, 2028. The trial is sponsored by the University of Arizona.
